BioCentury on BioBusiness,
Emerging Company Profile
Norway's Targovax developing vaccine targeting mutant Ras for pancreatic cancer
Related tables, figures and sidebars
Targovax: Ras to the rescue
Monday, November 12, 2012
A/S's peptide-based vaccine improved survival in an investigator-led
Phase I/II trial in resected pancreatic cancer, and the company is planning its
own Phase I/II trial this year. The vaccine works by going after mutant Ras, a
protein found in several types of cancer but generally considered a marker of
non-response to treatment instead of a therapeutic target.
Mutations in the Ras family of
genes - K-Ras (KRAS), v-Ha-ras Harvey rat sarcoma viral oncogene homolog (HRAS)
and neuroblastoma Ras viral (v-Ras) oncogene (NRAS) - are markers of resistance
to standard therapies in colorectal cancer (CRC) and non-small-cell lung cancer
(NSCLC) and are also found in up to 90% of pancreatic cancers.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2015 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]